Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma

Diabetic eye: associated diseases, drugs in clinic, and role of self-assembled carriers in topical treatment

“…Latanoprost-loaded niosomes (8-10 μm size) were dispersed in Pluronic F127 gel (drug concentration 0.005%) and the effects on IOP were monitored after instillation (50 μL) in the cul-de-sac of rabbit eyes. Latanoprost-loaded niosomes reduced IOP for 3 days, which was remarkably longer than the outcome achieved with the standard latanoprost eye drops (Xalatan ® ; 0.005%) (Figure 6) [167]. Proniosomal gel formulations are promising also for other anti-glaucoma agents, including dorzolamide hydrochloride and brimonidine tartrate [168,169].…”

Pre‐clinical and clinical applications of thermoreversible hydrogels in biomedical engineering: a review

“…192 Several poloxamers are commercially available, differing in composition and molar mass (MM). 34,[192][193][194] The most commonly used poloxamer in TRG-related studies is poloxamer 407 (Pluronic® F127, MM ≈ 12.6 kg mol −1 and EG 70 wt%), 6,[43][44][45][46][47][48][49][50][51][52][53][54][55][56]195,196 as this poloxamer gels at lower temperatures and concentrations compared to the other members of the family. 34 More specifically, it has been reported that poloxamer 407 gels at 12.6 w/v% in phosphate buffered saline (PBS), when purified appropriately, while gelation is not observed when the concentration is reduced to 11.6 w/v%.…”

“…without any polymer additives that would act as gelation modifiers, were applied in vivo have been reported in the literature. 6,[43][44][45][46][47][48][49][50][51][52][53][54][55][56]195,196 Most of the studies have used solutions of poloxamer 407 at 20 w/w% and higher, due to the higher stability and strength of the gel; however, a few studies have attempted the application at 15 w/w%. In TE, the gel was used to replace the nucleus pulposus, which acts as a shock absorber, in the intervertebral disc in dogs, and it was proven to be effective in resisting the strain applied for at least a period of 3 months.…”

“…44 In another study, bone mesenchymal stromal cells (BMSC) and chondrocytes were incorporated in the gel matrix, and the TRG system led to chondrogenic differentiation of BMSC. 43 In the drug delivery concept, solutions of P407 were investigated in vivo as carriers for HIV-1 lentiviral vector, 56 quetiapine fumarate, 55 latanoprost, 196 paclitaxel (PTX), 54 lapatinib, 54 vancomycin, 53 brimonidine tartrate, 51,52 rapamycin, 50 halobetasol propionate, 49 polyphenol tannic acid, 48 dapsone, 6 soy isoflavone, 47 RNA polymerase I inhibitor 46 and simvastatin. 45 This indicates the wide variety of diseases, ranging from cancer 50,54 to chronic otitis, 53 ocularrelated diseases, 51,52 acne, 6 intimal hyperplasia 45 and wound healing, 6,47,48 for which TRGs have been in vivo tested as drug delivery carriers.…”

“…52,54 An approach which has been proven to be effective in improving the drug bioavailability is to incorporate the drug molecules in particles, such as liposomes and niosomes, prior to their incorporation in the gel matrix. 47,[49][50][51][52]55,196 Formulations based on mixtures of poloxamers have also been investigated as in vivo injectable systems. 59,[65][66][67][68][69][70][71][72][73] This strategy has been applied in an attempt to control the thermogelling properties of the final system as desired.…”